Many patients with multiple sclerosis relapse or experience continued disease progression despite disease-modifying therapies, such as interferon β. This Review explores responses to interferon β treatment in patients with multiple sclerosis, discusses early identification of nonresponders, and describes a practical approach for incorporating clinical data, biological markers and MRI measures of disease activity into the management of these patients.
- Joep Killestein
- Chris H. Polman